Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time pointsX-TOLE2 data featured in ...

Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median ...

A video of Yareli Jessica Gijon having a seizure in class has gone viral reaching over 13 million views ...

Investigational azetukalner met its primary endpoint of reducing focal onset seizure frequency across two doses, initial findings from the phase III X-TOLE2 trial showed. Over 12 weeks, adjunctive ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug ...

BOSTON and SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE)-- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and ...

Xenon Pharmaceuticals Inc. ( XENE) Bank of America Global Healthcare Conference 2026 May 14, 2026 11:00 AM EDT ...

Epilepsy in children is a chronic neurological condition characterised by two or more unprovoked, recurring seizures resulting from sudden, abnormal electrical activity in the brain, affecting ...

A novel cell therapy is safe and effective in patients with drug-resistant mesial temporal lobe epilepsy and could eventually offer an alternative intervention.

Speakers warn that transient neurologic events may conceal high-risk vascular disease, seizures, or amnestic syndromes ...

Epilepsy is a neurological disorder that causes temporary brain dysfunction. The aftermath of an epileptic seizure varies for each individual and depends on its severity. FITBOOK outlines types of ...